A practical reference on reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Nuclear fission products are the atomic fragments left after a large atomic nucleus undergoes nuclear fission. Typically, a large nucleus like that of uranium fissions by splitting into two smaller nuclei, along with a few neutrons, the release of heat energy (kinetic energy of the nuclei), and gamma rays. The two smaller nuclei are the fission products. (See also Fission products (by element)). About 0.2% to 0.4% of fissions are ternary fissions, producing a third light nucleus such as helium-4 (90%) or tritium (7%). The fission products themselves are usually unstable and therefore radioactive. Due to being relatively neutron-rich for their atomic number, many of them quickly undergo beta decay. This releases additional energy in the form of beta particles, antineutrinos, and gamma rays. Thus, fission events normally result in beta and additional gamma radiation that begins immediately after, even though this radiation is not produced directly by the fission event itself. The produced radionuclides have varying half-lives, and therefore vary in radioactivity. For instance, strontium-89 and strontium-90 are produced in similar quantities in fission, and each nucleus decays by beta emission. But 90Sr has a 30-year half-life, and 89Sr a 50.5-day half-life. Thus in the 50.5 days it takes half the 89Sr atoms to decay, emitting the same number of beta particles as there were decays, less than 0.4% of the 90Sr atoms have decayed, emitting only 0.4% of the betas. The radioactive emission rate is highest for the shortest lived radionuclides, although they also decay the fastest.
== Contraindications == The US approval lists the thyroid C cell cancers medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2) as contraindications because other GLP-1 agonists are known to cause such cancers in rodents. Albiglutide causes immunogenicity in rodents, so its cancer risk could not be assessed. The European approval mentions the uncertainty about C cell cancers, but not as a contraindication.
Merabishvili said that Russian troops passed the Roki Tunnel at 3:00 AM on 7 August because they couldn't be photographed in the darkness of the night. He cited Dmitry Sanakoev as having reported that Russia supplied tanks during the cloudy days so Americans would not record the movement of tanks from Russia into South Ossetia. Merabishvili said that the government had no choice: "If we lost the territory without resistance, the public society of Georgia would not forgive us." Merabishvili suggested that Georgia won time by fighting back the Russian troops and saved Tbilisi. On 25 November 2008, Erosi Kitsmarishvili, Georgia's former ambassador to Russia, gave a testimony to a parliamentary commission in which he said that Georgian authorities were preparing for the conflict. According to Kitsmarishvili, he was told by Georgian officials in April 2008 that the United States approved a war in Abkhazia, but later the Georgian authorities made the decision to launch the war in South Ossetia. According to him, "Russia was ready for this war, but the Georgian leadership started the military action first."
Hydrogen peroxide has a relatively elusive and highly unstable isomer called oxywater, also known as water oxide. Its chemical formula is H2OO and its systematic IUPAC name is oxidooxidanium. It is isoelectronic to fluoroamine and is a ylide. It rapidly decomposes to form hydrogen peroxide, the reaction mechanism for which is likely a 1,2-hydrogen shift.
Sources: en.wikipedia.org
=== March === 11 March – Clive Revill, actor (The Empire Strikes Back, Irma La Douce, Oliver!) (born 1930). 13 March – Brian McMahon, venereologist, army officer, medical superintendent (Wakari Hospital, Dunedin Hospital) and lecturer (University of Otago) (born 1929). 14 March – Anne Nightingale, nurse, chair of the Nursing Council (1975–1984) (born 1932). 16 March – Gordon H. Brown, art historian, gallery director (Waikato Art Gallery, Sarjeant Gallery), and artist (born 1931). 20 March – Matt Mitchell, sailor (Team New Zealand, Alinghi, Oracle Team USA) (born c. 1971). 21 March – Nick Carter, lawyer and judge, Māori Land Court judge (1989–2002) (born 1935). 22 March – Alex Wyllie, rugby union player (Canterbury, national team) and coach (Canterbury, national team, Argentina) (born 1944). 31 March Sir Roger Clifford, 7th Baronet (born 1936). Ron Jones, obstetrician and gynaecologist (National Women's Hospital, University of Auckland), whistleblower in the "Unfortunate Experiment" (born 1939).
Hydrophobic interaction chromatography (HIC) can also be used for first and/ or intermediate steps. Selectivity in HIC is independent of running pH and descending salt gradients are used. For HIC, conditioning involves adding ammonium sulfate to the sample to match the buffer A concentration. If HIC is used before IEC, the ionic strength would have to be lowered to match that of buffer A for IEC step by dilution, dialysis or buffer exchange by gel filtration. This is why IEC is usually performed prior to HIC as the high salt elution conditions for IEC are ideal for binding to HIC resins in the next purification step. Polishing is used to achieve the final level of purification required and is commonly performed on a gel filtration column. An extra intermediate purification step can be added or optimization of the different steps is performed for improving purity. This extra step usually involves another round of IEC under completely different conditions. Although this is an example of a common purification protocol for proteins, the buffer conditions, flow rates, and resins used to achieve final goals can be chosen to cover a broad range of target proteins. This flexibility is imperative for a functional purification system as all proteins behave differently and often deviate from predictions.
The Federal Office for Radiation Protection's monitoring network measures natural radiation exposure through the local dose rate (ODL), expressed in microsieverts per hour (μSv/h). In Germany, the natural ODL ranges from approximately 0.05 to 0.18 μSv/h, depending on local conditions. The ODL monitoring network has been operational since 1973 and currently comprises 1800 fixed, automatically operating measuring points. Its primary function is to provide early warning for the rapid detection of increased radiation from radioactive substances in the air in Germany. Spectroscopic probes have been successfully utilized since 2008 to determine the contribution of artificial radionuclides in addition to the local dose rate, showcasing the network's advanced capabilities. In addition to the ODL monitoring network of the Federal Office for Radiation Protection, there are other federal monitoring networks at the Federal Maritime and Hydrographic Agency and the Federal Institute of Hydrology, which measure gamma radiation in water; the German Meteorological Service measures air activity with aerosol samplers. To monitor nuclear facilities, the relevant federal states operate their own ODL monitoring networks. The data from these monitoring networks are automatically fed into the Integrated Measurement and Information System (IMIS), where they are used to analyze the current situation. Many countries operate their own ODL monitoring networks to protect the public. In Europe, these data are collected and published on the EURDEP platform of the European Atomic Energy Community.
Sources: en.wikipedia.org
=== PT Prachuap === Townsend left Kanchanaburi following their relegation from the top flight and joined fellow Thai club PT Prachuap in August 2026. In September 2026, Townsend was run over by a pitch roller during warmup for a league match, in what has been described as "a bizarre incident". He reportedly avoided serious injury.
Furious about being woken early, Viktor refuses to believe Selene's warnings about Kraven's treachery and reminds her that his fellow elder Marcus was supposed to be awakened before him. Meanwhile, en route to the mansion to awaken Marcus, vampire elder Amelia, the coven's current ruler, is ambushed and killed by Lycans, who have tracked her with Kraven's assistance. Selene escapes the mansion and abducts the Lycan scientist Singe, while the Lycans capture Michael. While held captive in the Lycans' lair, Michael soon learns that Lucian was once in love with Viktor's daughter Sonja. After he discovered their forbidden affair, Viktor murdered her. Lucian claims that Lycans were once slaves of vampires, and the war began when they rose up against them and fought for their freedom. At the vampires' mansion, a captive Singe reveals that Selene was being honest about Kraven's betrayal, and he reveals why the Lycans want Michael: vampires and Lycans actually have a common ancestor, which Michael is a direct descendant of. As an heir to the legendary "Corvinus" bloodline, he carries a unique genetic strain that could allow him to become a vampire-werewolf hybrid, which Singe predicts will lack the weaknesses of both species. An angered Viktor then kills Singe and mobilizes the Death Dealers to raid the Lycan’s lair to kill the remaining Lycans, including Michael. In the ensuing showdown between vampires and Lycans, Selene breaks into the Lycans' lair to rescue Michael.
Research shows that co-administration with carbidopa greatly increases plasma 5-HTP levels. Other studies have indicated the risk of a scleroderma-like condition resulting from the combination of 5-HTP and carbidopa. After oral administration, 5-HTP is absorbed by the upper intestine. The mode of absorption is not known, but presumably involves active transport via amino acid transporters. 5-HTP is adequately absorbed via oral cavity. With a decarboxylase inhibitor, the bioavailability of 5-HTP can be higher than 50%. 5-HTP is rapidly absorbed with a tmax of ≈1.5 h, and rapidly eliminated with a half-life of ≈1.5 – 2 h. Co-administration of a decarboxylase inhibitor (e.g., carbidopa, benserazide) doubles the half-life of 5-HTP to ≈ 3 – 4 h, and enhances exposure several-fold, depending on the dosing regimen. 5-HTP's short half-life (<2 hours) may inherently limit its therapeutic potential, as systemic 5-HTP exposure levels will fluctuate substantially even with relatively frequent dosing. Such exposure fluctuations are usually associated with increased adverse event burdens resulting from Cmax (time to maximal systemic concentration) drug spikes, and decreased clinical efficacy resulting from sub-therapeutic exposure for large parts of the day, when taken as a single dose unit or at intervals significantly larger than Cmax. It has been proposed that 5-HTP dosage forms achieving prolonged delivery would be more effective, as has been demonstrated many times with other pharmaceuticals with short durations of action.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.